Factors including Sgk1 have also been considered as the cause of decreased sensitivity of cytotoxic drug therapy by activating the GC-GR pathway in hepatocellular carcinoma and colon adenocarcinoma [39]. This evidence concerns the gene GCGR and hepatocellular carcinoma.